argenx SE

1 day ago · fool.com

Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations.

3 days ago · zacks.com

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

3 days ago · globenewswire.com

September 17, 2026 – 22:01PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced the results of the Extraordinary General Meeting of Shareholders and appointments of Thomas M. Brakel and Khurem Farooq as non-executive directors of the Company's Board of Directors.

4 days ago · defenseworld.net

Tidal Investments LLC lifted its position in argenex SE (NASDAQ: ARGX) by 97.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,362 shares of the company's stock after purchasing an additional 1,168 shares during the period. Tidal

6 days ago · seekingalpha.com

argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

19 days ago · fool.com

Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.

21 days ago · globenewswire.com

September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:

26 days ago · fool.com

Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.

1 month ago · defenseworld.net

argenx (NASDAQ: ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM. The study evaluated efgartigimod in a 52-week Phase II/III basket trial that enrolled patients with IMNM, DM

1 month ago · zacks.com

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.